Financial News
Regeneron Pharmaceuticals (NQ: REGN )
1,199.12
+11.46
(+0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Headline News about Regeneron Pharmaceuticals
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/04/25/abbvie-shutter.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/774032/growth-trend.jpg)
![](/next-assets/images/schema-image-default.png)
![](https://cdn.benzinga.com/files/images/story/2024/Doctor-Examining-A-Lung-Radiography_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2021/08/Stock-BullPaintedRushing-adobe.jpg)
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
Topics
Economy
Exposures
Interest Rates
![](https://cdn.benzinga.com/files/images/story/2024/04/11/REGN.png?width=1200&height=800&fit=crop)
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
Via Benzinga
Topics
Fraud
Exposures
Legal
![](https://www.investors.com/wp-content/uploads/2020/08/Stock-regeneron-01-shutt.jpg)
![](https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg)
![](https://investorplace.com/wp-content/uploads/2019/09/pills-1.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2024/03/TECHpic-brain-040124-shutt.jpg)
![](https://g.foolcdn.com/editorial/images/770130/physician-talking-to-patient.jpg)
![](https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/cancer_16.jpeg?width=1200&height=800&fit=crop)
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600.png)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://cdn.benzinga.com/files/images/story/2024/03/13/nvidia_2_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/768349/scientists-looking-at-screen-with-icons.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/767744/doctor-and-patient-in-a-hospital-room.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.